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Discussion
In ML patients with comparable pretransplant performance sta-
tus, there were no statistical differences in complications, engraft-
ment, cell count yield, cell viability, days of apheresis, platelet
transfusions, or mobilization regimen between older and younger
patients receiving autografts. However, younger patients appeared
to require greater RBC blood product support (p0.05). Our data
suggests that older ML patients with good performance status can
be treated with autologous stem cell treatment strategies compa-
rable to those developed for younger patients.
Results
Variables/Age
Group <60 (N23) >60 p-value
Age (years) 43.9 {38.7, 49.1} 62.9 {60.5, 65.3} <.0001
Days of
Apheresis 2.87 {2.33, 3.41} 2.22 {1.48, 2.97} 0.18
CD 34 yield 5.06 {3.91, 6.20} 6.01 {3.37, 8.65} 0.28
Viability Day 1 83.8 {80.6, 87.0} 87.8 {83.4, 92.1} 0.15
Viability Day 2 84.5 {80.0, 88.2} 83.6 {74.8, 92.4} 0.76
Viability Day 3 82.9 {76.7, 89.0} 80.3 {53.5, 107} 0.57
Days to ANC
Engraftment 12.7 {11.6, 13.8} 12.0 {10.3, 13.7} 0.47
Days to PLT
Engraftment 15.5 {14.0, 17.0} 15.2 {13.6, 16.8} 0.75
Number of
PLT
Transfusions 3.17 {2.14, 4.21} 3.00 {1.41, 4.58} 0.95
Number of
RBC
Transfusions 3.96 {2.74, 5.18} 2.11 {1.35, 3.09} 0.05
Mobilization
Regimen
(%G) 57 67 0.70
Death <100
Days 4.4 0 1.00
Mucositis II-IV
<30 Days 30.4 0 0.15
Sepsis <30
Days 8.7 22.2 0.56
Pneumonia
<30 Days 8.7 0 1.00
Karnofsky
Score 97 99 1.00
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OUTCOME WITH A THIOTEPA CONTAINING REGIMEN AND AUTOLO-
GOUS HSCT IN PATIENTS WITH NHL
Cumpston, A.D.1, Bulian, D.A.1, Kanate, A.1, Weisenborn, R.1,
Bunner, P.1, Visweshwar, N.I.1, Craig, M.1, Ericson, S.G.1 1West
Virginia University Hospitals, Morgantown, WV.
Introduction: High dose chemotherapy and autologous hemato-
poietic stem cell rescue offers patients with advanced non-hodgkin
lymphoma (NHL) a chance for long-term survival and cure. The role
of thiotepa in this approach is still unknown, and little data with
long-term follow-up has been published. The best chemotherapy
regimen prior to stem cell infusion for patients with NHL remains
unknown.
Methods/Outcome: Twenty-nine patients with advanced NHL
were treated with high dose VP-16, cyclophosphamide, and thio-
tepa followed by autologous HSC rescue from 1993-2006. Median
age was 53 (range 27-69), and all patients except 2 were beyond
CR1. Overall survival and disease-free survival were 76% and 66%
respectively at a median follow-up of 44 months. Five patients
relapsed, with a median time to relapse of 150 days after transplant
(range 82-300 days). Treatment related mortality was 10% (3/29);
all 3 died from infectious complications before day 50. One patient
developed treatment-related myelodysplasia.
Conclusion: An aggressive preparative regimen for autologous
HSCT containing thiotepa offers patients a signiﬁcant chance for
long-term disease-free survival. However, caution is recommended
due to early infectious complications.
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IMMUNE MOBILIZATION OF AUTOLOGOUS PERIPHERAL BLOOD PRO-
GENITOR CELLS: IL-2 WITH GM-CSF AND G-CSF RESULTS IN EFFEC-
TIVE MOBILIZATION WITHOUT DELAY IN ENGRAFTMENT
Hill, J.M.1, Wu, J.-Y.1, Webber, S.1, Sharlin, O.1, Ernstoff, M.S.1,
Szczepiorkowski, Z.M.1, Meehan, K.P.1 1Dartmouth Hitchcock Medical
Center, Lebanon, NH.
We initiated an immune mobilization trial in an attempt to mobilize
cytotoxic effector cells, along with CD34 hematopoietic progenitor
cells. A Prospective Phase I trial was initiated using dose escalation of
IL-2, in combination with GM-CSF and G-CSF. IL-2 began on Day
0 and continued as a daily SQ injection for 11 days. On Day 7,
GM-CSF (7.5 mcg/kg/d) and G-CSF (5 mcg/kg/d) were initiated for
5 days (Days 7-11). On Day 11, leukapheresis was started if the
peripheral blood CD34 cell count was 5 cells/mcl. The endpoint
of collection was 3 106 CD34 cells/kg. After collection, patients
received melphalan (200 mg/m2) followed by infusion of cryopre-
served stem cells. Post-transplant GM-CSF began on Day 5 and
terminated once the ANC reached 5000 cells/mcl. To date, 10 pa-
tients have been treated (myeloma, n 9; NHL, n 1) and 9 patients
are evaluable. Dose escalation of IL-2 continues since the MTD has
not been reached. The ﬁrst two dose levels of IL-2 have been well
tolerated: Dose Level 1 (6 105 IU/m2/d; n 6 pts); and Dose Level
2 (1  106 IU/m2/d; n  3 pts). One patient has completed Dose
Level 3 (1.5  105 IU/m2/d) without difﬁculty. One patient (NHL)
was removed from the study due to progressive disease. The remain-
ing 9 patients completed the regimen. Toxicities have been mild and
have included Grade 2 fever (n1) on Dose Level 2. All patients were
successfully mobilized. The median number of CD34 cells/kg and
MNC/kg collected were 3.4  106 (range 2.8 – 4.4  106/kg) and
9.5  108 (range 0.4 – 1.7  109), respectively. Two large volume
leukaphereses were required (median; range 1 – 3). Following trans-
plant, the ANC recovered on Day 13 (median; range: 10 – 14 d) and
platelets recovered on Day 12 (median; range 0 – 13 d). These
preliminary results demonstrate that immune mobilization and col-
lection of an adequate number of hematopoietic progenitor cells is
feasible without suppression of hematopoiesis. Toxicities are minimal
but the MTD of IL-2 has not yet been reached. Post-transplant
engraftment is not delayed. As patient accrual continues, we are
currently evaluating the qualitative and quantitative components of
the collected cells, including Th1 vs. Th2 cells and the types of
dendritic cells mobilized, while evaluating lymphocyte recovery fol-
lowing transplant.
95
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT)
IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS OF A SYSTEM-
ATIC REVIEW
Kharfan-Dabaja, M.A.1, Kumar, A.1, Behera, M.1, Field, T.1,
Ayala, E.1, Perez, L.1, Fernandez, H.1, Anasetti, C.1, Djulbegovic, B.1
1H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FL.
Background: Despite improvements in responses, CLL remains
incurable with conventional chemotherapy (CC). About 1/3 of pa-
tients are  60 yrs, and are offered experimental therapies including
high-dose chemotherapy (HDT) and auto-HCT. The objective of
this study is to present the totality of the evidence by conducting a
systematic review to assess the efﬁcacy of auto-HCT in the treatment
of CLL. Methods: A systematic search of the literature was per-
formed using MEDLINE databases (1966- Sep 12, 2006) and hand-
search of references. Included studies were prospective-randomized,
non-randomized or single-arm trials. Data were extracted on primary
outcomes (response rate (RR), overall survival (OS), progression-free
survival (PFS) etc.). Results: Our search identiﬁed altogether 82
publications. Only 8 met our pre-determined inclusion criteria (ta-
ble1). In this cohort of 8 trials, 2 trials were funded by public/
government sources, 2 by private foundations, 1 was funded jointly by
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private and public sources, and was unclear in the remaining 3. There
were no randomized controlled trials evaluating auto-HCT in CLL.
Five studies were single-arm trials and 3 were non-randomized trials
with a control arm (autologous vs. allogeneic). Median age for pts
receiving auto-HCT ranged from 45 to 59 years. When allogeneic
HCT was the control arm, the median age ranged from 40 to 47
years. The cumulative number of pts receiving auto-HCT is 403 (M
294, F 109). Primary endpoints in the trials were: CR (clinical or
molecular) 4; OS2; PFS1; engraftment1. Median clinical re-
sponse rates from 6 studies ranged from 54.5 % to 89.4% at 3 to 20
months. Molecular response in one study was 76.9%. Overall survival
at 3 to 6 years in 4 studies were 88.6% to 58%. Median progression-
free survival in 3 studies were 92.3 % at 4 years to 30% at 6 years.
Conclusion: The evidentiary base to recommend HDT and auto-
HCT as standard practice in CLL is limited. Improved response rates,
especially molecular responses are encouraging. It is uncertain
whether auto-HCT is superior to CC as a salvage strategy, but data
appears promising to take it to a formal testing in a randomized study.
Table 1:
Studies identiﬁed in Medline and hand-search of references
(N82)
Not included (N74) [Reviews18, Not clinical outcome17,
not clinical trial13, not transplant trial12, not CLL8, not in
English3, prognostic-marker studies3]
Eligible studies (N8) [single-arm trials5, non-randomized
comparison3]
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AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION: REGIMEN RE-
LATED COMPLICATIONS AND TRANSPLANT OUTCOME
Kumar, L.1, Ganessan, K.1, Khatry, N.1, Sengar, M.1, Sharma, A.1
1All India Institute of Medical Sciences, New Delhi, India.
Purpose : To determine the transplant related complications
after autologous peripheral blood stem cell transplantation (ASCT)
and overall outcome.
Design : Cohort study of 144 consecutive patients.
Setting : A tertiary care centre
Patients and Methods : 144 consecutive patients (median age 47.5
years, range, 11 to 68 years) underwent ASCT. There were 102 males
and 42 females. Indications for transplant were : multiple myeloma-
78(54.2%), Hodgkin’s-14(9.7%), non Hodgkin’s lymphoma-
14(9.7%), acute leukemia 17, CML -5(3.5%), solid tumours
-16(10.7%). Patients received G-CSF mobilized peripheral blood
stem cells (PBSC). All patients were treated in a single room with
reverse barrier nursing without laminar air ﬂow or HEPA ﬁlter. High
dose (HD) chemotherapy was given using standard protocols . Organ
toxicity was assessed according to Seattle criteria and response to
transplant as per standard guidelines.
Results : 126 of 144 patients engrafted. 19 (13.2%) patients died
prior to day 30. The causes of death were sepsis with or without
multi-organ failure (n-12) and regimen related toxicity-7 (4.2%). Fac-
tors like poor performance status , progressive or refractory disease at
transplant and failure to engraft by day 18 were associated with
increased risk of day 30 mortality. GIT toxicity, mucositis, veno-
occlusive disease, liver and renal dysfunction were main regimen
related toxicities; GIT toxicity and mucositis was signiﬁcantly higher
among patients who received HD melphalan for conditioning. Post
transplant, CR rate was signiﬁcantly higher in chemosensitive disease
group (70%) compared to 20% in chemo-refractory disease, p.01.
The median overall survival (OS) for all patients is 55 months 
9.07(CI 37.22-72.78) with estimated OS at 2 and 5 years being 66.5%
and 45%, respectively. Event - free survival (EFS) for the whole group
is 24 months  5.13(13.94-34.06) with probability of EFS 2 and 5
years being 47.2 %, and 41%, respectively . Survival was signiﬁcantly
better for patients with chemo-sensitive disease at transplant (median
OS 89 months vs 18 months,p.0001). Patients who were in CR post
transplant had a signiﬁcantly better overall survival . Currently, 60 of
126 patients (47.6%) are alive at a median follow up of 3 years. 66
patients have died predominantly due to relapse - 57/66 (86.4%).
Conclusion : Good primary pre-transplant management and
careful case selection are two important factors associated with
good transplant outcome.
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RITUXIMAB-RELATED LATE-ONSET NEUTROPENIA AFTER AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR MALIGNANT LYMPHOMA
Nagafuji, K.1, Numata, A.1, Yoshimoto, G.1, Harada, N.1,
Harada, M.1 11st Dep of Internal Medicine, Kyushu University Hospi-
tal, Fukuoka, Japan.
Rituximab (Rit) chimeric human/mouse monoclonal antibody
directed against the CD20 antigen. It can be used before stem cell
harvest as a way of in vivo purging or after stem cell transplantation
as an adjuvant therapy.
Recently, several cases of late-onset neutropenia (LON) have
been described in relation to its utilization in stem cell transplan-
tation as well as chemotherapy setting.
The reason why Rit induces neutropenia was poorly understood.
Dunleavy reported that perturbation of SDF-1 during B-cell re-
covery retards neutrophil egress from the bone marrow as a mech-
anism of Rit-induced neutropenia (Blood, Vol. 106, 795-802).
We retrospectively analyzed the incidence of LON in autologous
peripheral blood stem cell transplantation (autoPBSCT) for malig-
nant lymphoma (ML) using Rit, autoPBSCT forMLwithout Rit, and
autoPBSCT of CD34 cells for refractory autoimmune disease (AD).
Methods
LON was deﬁned as neutrophil count less than 1,000/l after
achieving durable hematopoietic engraftment without apparent
reasons including myelotoxic drug, viral infection, or disease pro-
gression. The hematologic data of out patient clinics were retro-
spectively analyzed.
Results
The incidence of LON was 64.3% in autotransplanted ML with
Rit. The Nadir of LON was 69-751 (median 578) /l. The onset
of LON from transplant was 61-128 (median 80) days. The dura-
tion of LON was 14-124 (median 56) days. There were no LON-
related infectious complications.
The incidence of LON of autotransplanted ML without Rit and
autotransplanted AD was 8.3%, and 10%, respectively.
Conclusion When Rit was used peri-autotransplant period, the
incidence of LON was increased. Since autotransplantation with
puriﬁed CD34 cells did not increase the incidence of LON, our
analysis results could not support the idea that perturbation of
SDF-1 during B-cell recovery retards neutrophil egress from the
bone marrow as a mechanism of Rit-induced neutropenia.
Results AD using
CD34
cells
(n10)
ML with Rit
(n14)
ML without Rit
(n12)
age(median) 14-59(54) 31-68(50) 21-63
(54)
sex (M/F) 7 / 7 10 / 2 3 / 7
disease DLBL 12, FL 2 DLBL 6, PTCL
2, LBL 1, MCL
1, 2
SSc 7,
SLE 1,
DM/IP 1,
WG 1
disease status 1CR 11, 1Rel
2, 2CR 1
1CR 8, 1PR 2,
Ref 2
No. of infused
CD34 cells
7.4 (3.9 -13.9)
10e6/kg
8.3 (1.4-24.5)
10e6/kg
4.9 (2.0
-16.0) )
10e6/kg
Conditioning R-MCEC 10,
MCEC 3, 2
MCEC 10, TBI
1, 1
HD-CY
LON 9 (64.3%) 1(8.3%) 1(10%)
Neutoropenia of
known reason
VZV 2 Drug 1 CMV 1
observation period
(median)
121-929 (276) 148-1715 (860)
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